Home » Topics » Regulatory » EMA

EMA
RSS

Ignyta's entrectinib obtains PRIME designation from EMA

Oct. 18, 2017

EMA's CHMP supports expansion of marketing authorization for Zytiga

Oct. 16, 2017

EMA accepts Imfinzi MAA for locally advanced unresectable NSCLC

Oct. 9, 2017

EMA accepts Cinfa's MAA for biosimilar pegfilgrastim B-12019

Oct. 6, 2017

Ruconest provides clinically meaningful relief of symptons in phase II study

Oct. 2, 2017

EMA grants orphan drug designation to EDIT-101 for LCA10

Sep. 27, 2017

EMA committee recommends approval of 10 mg rivaroxaban for extended prevention of VTE

Sep. 19, 2017

CHMP issues positive opinion for Zejula

Sep. 18, 2017

Boehringer Ingelheim receives positive opinion for adalimumab biosimilar Cyltezo

Sep. 18, 2017

EMA committee recommends approval of guselkumab for moderate to severe plaque psoriasis

Sep. 18, 2017

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...